| Spending, utilization, and price trends for immune checkpoint inhibitors in US medicaid programs: an empirical analysis from 2011 to 2021 YE Shin, A Kumar, JJ Guo Clinical Drug Investigation 43 (4), 289-298, 2023 | 9 | 2023 |
| Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis YE Shin, S Rojanasarot, AL Hincapie, JJ Guo Sexual Medicine 11 (5), qfad059, 2023 | 4 | 2023 |
| PNS243 Review of Patient Reported Outcome (PRO) Measures for Novel Drug Approvals (NDA) in the United States: 2016-2018 YE Shin, SB Kim, Z Zheng, J Muzumdar, W Wu Value in Health 22, S327, 2019 | 1 | 2019 |
| PD46-12 SURGEON VOLUME IN PENILE PROSTHESIS IMPLANTATION CORRELATES WITH RE-OPERATION RATES—NATIONAL MEDICARE ANALYSIS N Leelani, T Furtado, J Andino, Y Shin, S Rojanasarot, R Sato, H Bernie, ... The Journal of Urology 211 (5S), e979, 2024 | | 2024 |
| MP57-20 ANTIDEPRESSANT MEDICATION USE AMONG COMMERCIALLY INSURED MEN WITH DEPRESSION UNDERGOING INFLATABLE PROSTHESIS IMPLANTATION R Golan, Y Shin, AM McGovern, R Paranjpe, S Rojanasarot, T Kohn, ... Journal of Urology 211 (5S), e946, 2024 | | 2024 |
| (358) Improved Healthcare Utilization Among Men with Depression Undergoing Inflatable Penile Prosthesis in a United States Commercial Population R Golan, R Paranjpe, Y Shin, S Rojanasarot, S Nackeeran, F Petrella, ... The Journal of Sexual Medicine 21 (Supplement_1), qdae001. 343, 2024 | | 2024 |
| (241) Optimizing Care-Economic Impact of Reduced Teaching Visits After IPP Implantation B Gill, YE Shin, K Durand, S Rojanasarot The Journal of Sexual Medicine 21 (Supplement_1), qdae001. 231, 2024 | | 2024 |
| (373) Economic Benefits of Patient Care for Prostate Cancer Survivors with Stress Urinary Incontinence and/or Erectile Dysfunction: A Physician Reimbursement Analysis P Babbar, S Rojanasarot, YE Shin, A Sun The Journal of Sexual Medicine 21 (Supplement_1), qdae001. 358, 2024 | | 2024 |
| (240) Evaluation of Factors Associated with Reoperation Rates for Penile Prosthetic Implantation in Erectile Dysfunction: A Medicare Analysis J Andino, N Leelani, S Rojanasarot, Y Shin, R Paranjpe, HL Bernie, ... The Journal of Sexual Medicine 21 (Supplement_1), qdae001. 230, 2024 | | 2024 |
| Pharmacists’ facilitators and barriers to implementing and billing for patient care services: Interviews from the Ohio Medicaid Project R Lahrman, YE Shin, B Porter, S Beatty, AL Hincapie Journal of the American Pharmacists Association 63 (4), 1077-1086, 2023 | | 2023 |
| EPH140 Safety of PDE-5 Inhibitors for Erectile Dysfunction: Descriptive and Disproportionality Analyses of the FDA Adverse Event Reporting System (FAERS) Database from 2010 to 2022 YE Shin, S Rojanasarot, AL Hincapie, JJ Guo Value in Health 26 (6), S189-S190, 2023 | | 2023 |
| EPH25 Adverse Drug Events Associated with Immune Checkpoint Inhibitors Atezolizumab, Nivolumab and Pembrolizumab: A Descriptive Retrospective Pharmacoepidemiologic Analysis … A Singh, AL Hincapie, JJ Guo, YE Shin Value in Health 26 (6), S168, 2023 | | 2023 |
| Cost-Utility Analysis Comparing Direct Oral Anticoagulant and Low Molecular Weight Heparin Therapies for Secondary Prevention of Cancer-Associated Thrombosis YE Shin, A Kumar, M Hwang, M Mackey, W Wu Clinical Drug Investigation 42 (12), 1075-1083, 2022 | | 2022 |
| EE504 Cost-Utility Analysis Comparing Direct Oral Anticoagulant (DOAC) and Low-Molecular-Weight Heparin (LMWH) Therapies for Cancer-Associated Thrombosis (CAT) Treatment in the … YE Shin, M Hwang, ML Mackey, A Kumar, WK Wu Value in Health 25 (7), S433, 2022 | | 2022 |
